Crinetics Pharmaceuticals gained FDA approval for Palsonify (paltusotine), the first oral once-daily therapy to treat adult acromegaly patients who are either post-surgery inadequate responders or ineligible for surgery. This approval positions Crinetics against established injectable acromegaly treatments from Novartis and Ipsen, potentially reshaping the therapeutic market for this rare endocrine disorder marked by excessive growth hormone production. The drug’s novel oral administration offers a convenient alternative to injections, expanding options for patients managing this chronic condition.